Neurothera
Labs

(TSXV: NTLX)

Late-Stage Innovative Clinical Company Redefining CNS Treatment

Neurothera Labs at Glance

We are revolutionizing cannabinoid-based treatments by developing proprietary pharmaceuticals that increase patients’ safety by reducing doses while maintaining effectiveness

About
Advanced Pipeline
3 programs in advanced
stages
IP Portfolio
Strengthened
IP portfolio
Strategic Partnership
Collaboration in the Neuroplastogens-based therapies

Technology

Learn More
Platform SCI-110
THC (Tetrahydrocannabinol) + CannAmideTM
Tourette Syndrome
(TS)
Alzheimer’s Disease (AD)
and agitation
Obstructive Sleep
Apnea (OSA)
Platform SCI-220
CBD (Cannabidiol) + CannAmideTMTM
Autism Spectrum
Disorder (ASD)
Status Epilepticus
(SE)

Management

A leadership team combining deep capital markets experience, clinical R&D expertise, and decades of operational execution in complex corporate environments.

Meet the team

Neurothera Labs Inc. holds approximately 54% ownership in CliniQuantum Ltd.

A private technology company developing a cutting-edge quantum computing platform for clinical trial data analysis.

CliniQuantum